Patients who received sutimlimab experienced meaningful increases in hemoglobin levels and normalization of bilirubin levels.
Novartis announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.
A systematic literature review showed that erythropoietin-stimulating agents positively influenced outcomes of patients with MDS-associated anemia.
The long-term outcomes of limiting the frequency of red blood cell transfusions in patients with anemia had not previously been described.
Researchers assessed 266 pregnant women with and without sickle cell disease in Ghana to determine the effect of a multidisciplinary care strategy.
Allogeneic hematopoietic cell transplantation was tolerated well by pediatric patients with sickle cell disease and transfusion-dependent thalassemia.
Results from a study in which patients with Fanconi anemia underwent a reduced intensity conditioning regimen followed by bone marrow transplantation.
The efficacy, safety, and feasibility of using hydroxyurea as a therapeutic agent for sickle cell anemia have not been assessed in many populations.
Investigators conducted a systematic review of 7083 studies to evaluate the association between sickle cell trait and any of 24 adverse clinical outcomes.
Children born with sickle cell disease in low-resource regions of the world often remain undiagnosed and therefore do not receive appropriate treatment.
The approval was based on data from a single-arm, open-label sequential cohort study in which patients received Promacta in combination with horse antithymocyte globulin (h-ATG) and cyclosporine.
More than one-third of nonanemic patients admitted to Royal Perth Hospital in Australia developed anemia during their stay.
Researchers analyzed prospective follow-up data from 702 patients with Diamond-Blackfan anemia for cancer incidence and risk.
Anemia with a baseline hemoglobin <13 g/dL was associated with a more than 5-fold increased risk for contrast-induced acute kidney injury in patients undergoing coronary angiography.
The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data which demonstrated a high degree of similarity between Retacrit and its reference product.
Using the infarct heat map, the investigators determined that infarct density was higher in the deep white matter and co-localized with the elevated OEF region in the independent prospective cohort.